Validation of the Italian version of the Charcot-Marie-Tooth Health Index.


Journal

Journal of the peripheral nervous system : JPNS
ISSN: 1529-8027
Titre abrégé: J Peripher Nerv Syst
Pays: United States
ID NLM: 9704532

Informations de publication

Date de publication:
09 2020
Historique:
received: 24 05 2020
accepted: 26 05 2020
pubmed: 9 6 2020
medline: 28 9 2021
entrez: 9 6 2020
Statut: ppublish

Résumé

The Charcot-Marie-Tooth Health Index (CMT-HI) is a disease-specific patient-reported outcome measure measuring overall disease burden in Charcot-Marie-Tooth (CMT) patients, designed for natural history studies and clinical trials in English-speaking affected individuals. We developed and validated its Italian Charcot-Marie-Tooth Health Index (I-CMT-HI) version. The questionnaire was translated and culturally adapted from source into Italian by two neurologists experienced in CMT and neuromuscular disorders (NMDs). The two translations were reviewed by a panel of seven experts in CMT and NMD. The provisional version was back-translated into English by a professional translator. The definitive Italian version was developed during a consensus teleconference by the panel and a patient representative from ACMT-Rete. A series of clinically and genetically characterized CMT patients completed the final questionnaire; 11 participated in a test-retest reliability assessment of the instrument. The I-CMT-HI was administered to 30 CMT patients (13 CMT1A, eight CMTX1, two CMT1B, two CMT1E, two CMT2I, one CMT2A, one CMT2N, one distal Hereditary Motor Neuropathy), with test-rest in 11:14 females and 16 males, aged (mean ± SD) 48.0 ± 16.4 years (range 18-81), with CMT Examination Score (CMTES) = 10.0 ± 4.4 (range 2-18). The I-CMT-HI mean total score was 29.4 ± 21.2 (range 0.1-60.3). The I-CMT-HI showed a high test-retest reliability: intraclass correlation coefficient = 0.95 (95% confidence interval, 0.84-0.99). No patient had difficulty in completing the questionnaire and none reported any problem with the questions' formulation. The total CMT-HI score was positively correlated with age and CMTES, with higher disease burden with increasing age and disease severity according to the CMTES. The I-CMT-HI is now ready for use in clinical studies in the Italian population.

Identifiants

pubmed: 32511835
doi: 10.1111/jns.12397
pmc: PMC7484132
mid: NIHMS1619317
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

292-296

Subventions

Organisme : NINDS NIH HHS
ID : U01 NS109403
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS065712
Pays : United States

Informations de copyright

© 2020 Peripheral Nerve Society.

Références

Eur J Neurol. 2015 Dec;22(12):1556-63
pubmed: 26227902
Curr Opin Neurol. 2017 Oct;30(5):471-480
pubmed: 28678038
Ann Neurol. 2018 Aug;84(2):225-233
pubmed: 30014533
Brain Res. 2020 Feb 15;1729:146625
pubmed: 31899213
Health Qual Life Outcomes. 2006 Oct 11;4:79
pubmed: 17034633
Value Health. 2005 Mar-Apr;8(2):94-104
pubmed: 15804318
J Peripher Nerv Syst. 2011 Sep;16(3):191-8
pubmed: 22003934

Auteurs

Chiara Pisciotta (C)

Unit of Rare Neurodegenerative and Neurometabolic Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Emma Ciafaloni (E)

Department of Neurology, University of Rochester, Rochester, New York, USA.

Riccardo Zuccarino (R)

Department of Neurology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.
Neuromuscular Omnicentre-Fondazione Serena Onlus, Arenzano, Italy.

Daniela Calabrese (D)

Unit of Rare Neurodegenerative and Neurometabolic Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Paola Saveri (P)

Unit of Rare Neurodegenerative and Neurometabolic Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Silvia Fenu (S)

Unit of Rare Neurodegenerative and Neurometabolic Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Irene Tramacere (I)

Unit of Rare Neurodegenerative and Neurometabolic Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Filippo Genovese (F)

ACMT-Rete per la malattia di Charcot-Marie-Tooth, OdV, Bologna, Italy.

Nuran Dilek (N)

Department of Neurology, University of Rochester, Rochester, New York, USA.

Nicholas E Johnson (NE)

Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA.

Chad Heatwole (C)

Department of Neurology, University of Rochester, Rochester, New York, USA.
Center for Health and Technology, University of Rochester, Rochester, New York, USA.

David N Herrmann (DN)

Department of Neurology, University of Rochester, Rochester, New York, USA.

Davide Pareyson (D)

Unit of Rare Neurodegenerative and Neurometabolic Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH